Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)

被引：0
|
作者：
Tuxen, M. K. [1 ]
Cold, S. [2 ]
Tange, U. B. [3 ]
Soendergaard, S. B. [4 ]
Nielsen, D. L. [1 ]
机构：
[1] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[3] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[4] Herlev Univ Hosp, Dept Nucl Med, DK-2730 Herlev, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S173 / S173
页数：1
相关论文
共 50 条
  • [11] Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer (vol 30, pg 3817, 2010)
    Artioli, Grazia
    Mocellin, Simone
    Borgato, Lucia
    Cappetta, Alessandro
    Bozza, Fernando
    Zavagno, Giorgio
    Zovato, Stefania
    Marchet, Alberto
    Pastorelli, Davide
    [J]. ANTICANCER RESEARCH, 2011, 31 (02) : 751 - 751
  • [12] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [13] A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2-Positive Breast Cancer Patients.
    Llombart-Cussac, A.
    Pernas-Simon, S.
    Rezai, M.
    Hauschild, M.
    Venturini, M.
    Machiels, J-P
    Paepke, S.
    Luporsi, E.
    Kasiborski, F.
    Kayitalire, L.
    [J]. CANCER RESEARCH, 2011, 71
  • [14] A multicenter randomized phase II study of nonpegylated liposomal doxorubicin plus vinorelbine versus nonpegylated liposomal doxorubicin plus cyclophosphamide as first line in locally advanced breast cancer (LABC) or metastatic breast cancer (MBC): Safety results
    Lorusso, V.
    Leo, S.
    Ciccarese, M.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Piano, A.
    Gebbia, V.
    Pisconti, S.
    Colucci, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [15] Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
    Limentani, Steven A.
    Brufsky, Adam M.
    Erban, John K.
    Jahanzeb, Mohammed
    Lewis, Deborah
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (10) : 1232 - 1238
  • [16] A phase II study of gemcitabine (G), peghilated liposomal doxorubicin (PLD) and docetaxel (D) in locally advanced breast cancer (LABC). Interim analysis
    Artioli, G.
    Bozza, F.
    Zovato, S.
    Mencarelli, R.
    Zavagno, G.
    Michelotto, M.
    Zustovich, F.
    Binato, S.
    Salmaso, F.
    Pastorelli, D.
    Cartei, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI14 - XI15
  • [17] NON PEGYLATED LIPOSOMAL DOXORUBICIN (MYOCET) PLUS VINORELBINE VERSUS MYOCET PLUS CYCLOPHOSPHAMIDE AS FIRST LINE IN LOCALLY ADVANCED (LABC) OR METASTATIC BREAST CANCER (MBC): A RANDOMIZED MULTICENTER PHASE II TRIAL
    Lorusso, V
    Leo, S.
    Forcignano, R.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Maiello, E.
    Gebbia, V
    Pisconti, S.
    Colucci, G.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [18] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] Non Pegylated Liposomal Doxorubicin (Myocet) Plus Vinorelbine Versus Myocet Plus Cyclophosphamide as First Line in Locally Advanced (Labc) or Metastatic Breast Cancer (Mbc): A Randomized Multicenter Phase II Trial
    Lorusso, V.
    Leo, S.
    Forcignano, R.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Maiello, E.
    Gebbia, V.
    Pisconti, S.
    Colucci, G.
    [J]. ONCOLOGY, 2009, 77 : 151 - 151
  • [20] A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
    Cheng, Meng
    Song, Zhenchuan
    Qi, Yixin
    Wang, Xinle
    Zhang, Lina
    Shi, Jiajie
    Wang, Mingxia
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 269 - 274
12345